MedTrace Logo

Trial of Montelukast in Eosinophilic Esophagitis

NCT00511316 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2015-11-03

No results posted yet for this study

Summary

Evaluate clinical effectiveness of oral montelukast compared to placebo on prevention of dysphagia and food impaction in patients with EE.

Also evaluate tolerance and safety of oral montelukast in treatment of EE.

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

Montelukast/ Singulair

20 mg daily for six months

DRUG

Placebo

Placebo 20 mg daily for 6 months

Sponsors & Collaborators

Principal Investigators

  • Jeffrey A. Alexander, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00511316 on ClinicalTrials.gov